{"nct_id":"NCT05883644","title":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-06","start_date":"2023-06-27","start_date_type":"ACTUAL","primary_completion_date":"2025-09-30","primary_completion_date_type":"ESTIMATED","completion_date":"2026-03-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}